Inhibrx, Inc.

Equities

INBX

US45720L1070

Biotechnology & Medical Research

Delayed Nasdaq 10:26:14 2024-06-14 am EDT 5-day change 1st Jan Change
16.5 USD -0.54% Intraday chart for Inhibrx, Inc. -7.94% -56.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing MT
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P TMI Index CI
Inhibrx, Inc. Announces Termination of Loan Agreement CI
Inhibrx, Inc. Announces Management Changes CI
Sanofi Closes Purchase of US Biotech Company Inhibrx MT
Sanofi: acquisition of Inhibrx finalized CF
Aventis Inc. completed the acquisition of Inhibrx, Inc. from a group of shareholders. CI
Inhibrx, Inc. completed the Spin-Off of 92% stake in Inhibrx Biosciences, Inc.. CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index CI
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi MT
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Inhibrx Shares Fall After Q4 Net Loss Widens MT
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M MT
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Arecor Therapeutics hails Arestat as 2023 performance "strong" AN
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results DJ
Health Care Flat After J&J Earnings -- Health Care Roundup DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi AN
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care MT
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion MT
CAC40: slight decline in the absence of catalysts CF
Chart Inhibrx, Inc.
More charts
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is a wholly owned subsidiary of Sanofi S.A.
Related indices
More about the company
  1. Stock Market
  2. Equities
  3. INBX Stock
  4. News Inhibrx, Inc.
  5. Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi